A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Fracture; Postmenopausal osteoporosis; Vertebral fracture
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 05 Oct 2013 According to the abstract presented at 35th Annual Meeting of the American Society for Bone and Mineral Research, the study was blinded at the time of submission, but was due to be unblinded and analyses completed by August 2013
- 13 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.